Skip to main content

Amid Shortages, U.S. Allows Expanded Production of ADHD Drug Vyvanse

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 5, 2024.

By Robin Foster HealthDay Reporter

THURSDAY, Sept. 5, 2024 -- The maker of the ADHD drug Vyvanse has been given approval by the U.S. Drug Enforcement Administration to make more of the medication as a shortage of the critical drugs continues.

Following a request from the U.S. Food and Drug Administration in July, the DEA said Thursday that Takeda Pharmaceuticals may now increase its production limit by 24%.

“These adjustments are necessary to ensure that the United States has an adequate and uninterrupted supply of lisdexamfetamine [Vyvanse] to meet legitimate patient needs both domestically and globally,” the DEA said in a notice it posted on the approval.

ADHD drugs have been in short supply for years. The FDA first warned of a shortage of Teva Pharmaceutical Industries’ Adderall medication in October 2022, as the company was plagued by manufacturing delays.

That prompted a spike in demand and subsequent shortage of Takeda’s Vyvanse.

Why was the DEA's approval to boost production needed? Vyvanse (lisdexamfetamine) is classified by the DEA as a schedule II controlled substance, which is applied to drugs considered to have a high likelihood of being abused, so additional prescribing safeguards are put in place.

The production limit for lisdexamfetamine was increased by 13, 478 pounds (6,236 kilograms), which includes 3,434 pounds (1,558 kg) to address domestic demand and 10,313 pounds (4,678 kg) for foreign demand for finished dosage medications, according to the DEA.

After Takeda lost exclusivity of Vyvanse last year, the FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma Pharmaceuticals and Indian drugmaker Sun Pharmaceutical Industries, Reuters reported.

Sources

  • U.S. Drug Enforcement Administration, notice, Sept. 4, 2024
  • Reuters

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

High Doses of ADHD Meds Could Trigger Psychosis

THURSDAY, Sept. 12, 2024 -- Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately...

Parents' Excessive Smartphone Use Could Harm Children's Mental Health

FRIDAY, Aug. 16, 2024 -- A child at the dinner table talks about trouble at school or an argument with a friend, but parents aren't listening: They're checking their smartphones...

Not Born Equal: Preemie Babies Fall Into 3 Risk Categories

WEDNESDAY, Aug. 14, 2024 -- Not all babies born prematurely will suffer long-term developmental problems, a new study finds. Preemies tend to fall into three risk categories...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.